ArticleJournal of clinical and experimental hematopathology : JCEH2023

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.

Masuho Saburi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.